株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗生物質:契約条件・合意内容

Global Antibiotics Partnering Terms and Agreements 2010 to 2016

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 270198
出版日 ページ情報 英文 219 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
抗生物質:契約条件・合意内容 Global Antibiotics Partnering Terms and Agreements 2010 to 2016
出版日: 2016年10月05日 ページ情報: 英文 219 Pages
概要

当レポートでは、抗生物質関連の各種提携契約の動向について調査分析し、大手製薬会社による各種提携の概要、契約区分・産業部門・開発段階・技術区分別の契約データのディレクトリーなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 抗生物質関連の各種提携動向

  • イントロダクション
  • 長年に渡る抗生物質提携
  • 大手製薬企業の抗生物質契約活動
  • 大手バイオテク企業の抗生物質契約活動
  • 最も活発な抗生物質契約
  • 抗生物質提携:契約タイプ別
  • 抗生物質提携:疾病タイプ別
  • 提携:抗生物質技術別
  • 抗生物質提携の平均契約条件
  • 抗生物質提携の構造
  • 抗生物質契約の構造

第3章 主要抗生物質契約

  • イントロダクション
  • 主要契約:金額別

第4章 大手製薬会社の抗生物質契約

  • イントロダクション
  • 大手製薬会社の抗生物質提携契約利用法
  • 大手製薬会社の抗生物質提携企業プロファイル

第5章 大手バイオテク会社の抗生物質契約

第6章 抗生物質提携契約ディレクトリー

  • イントロダクション
  • 企業別(A-Z)
  • 契約タイプ別
    • 資産購入
    • 大手医薬品企業のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同マーケティング
    • 業務委託
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売、など
  • 開発段階別
    • 創薬
    • 上市
    • 処方製剤
    • 第1相
    • 第2相
    • 第3相
    • 前臨床
    • 申請登録
  • 治療領域別
    • 心血管
    • 中枢神経系
    • 歯科
    • 皮膚科
    • 消化器科
    • 遺伝子疾患
    • 泌尿生殖器
    • ホスピタルケア
    • 免疫
    • 感染症
    • 代謝
    • 筋骨格
    • 精神科
    • 公衆衛生
    • 呼吸器
    • 性の健康

第7章 抗生物質契約:技術タイプ別

  • イントロダクション
  • 契約:抗生物質タイプ別

付録:提携リソースセンター

  • オンラインパートナリング
  • パートナリングイベント
  • 参考資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2119

The Global Antibiotics Partnering Terms and Agreements 2010 to 2016 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

  • Trends in antibiotics partnering deals
  • Disclosed headlines, upfronts, milestones and royalties by stage of development
  • Antibiotics partnering contract documents
  • Top antibiotics deals by value

The Global Antibiotics Partnering Terms and Agreements 2010 to 2016 report provides an understanding and access to the antibiotics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibiotics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors antibiotics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibiotics agreements announced in the healthcare sectors, covering:

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Penicillin
  • Quinolones
  • Sulfonamides
  • Tetracycline

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 200 links to online copies of actual antibiotics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

The initial chapters of this report provide an orientation of antibiotics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibiotics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading antibiotics deals since 2010. Deals are listed by headline value, signed by big pharma, most active antibiotics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibiotics dealmaking with a brief summary followed by a comprehensive listing of antibiotics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of antibiotics partnering deals signed and announced since Jan 2010. The chapter is organized by specific antibiotics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by antibiotics partnering company A-Z, deal type definitions and antibiotics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in antibiotics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibiotics technologies and products.

Report scope

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding and access to antibiotics trends and structure of deals entered into by leading companies worldwide.

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 includes:

  • Trends in antibiotics dealmaking in the biopharma industry since 2010
  • Analysis of antibiotics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibiotics deals
  • Access to over 200 antibiotics deal records and contract documents where available
  • The leading antibody deals by value since 2010
  • Most active antibiotics dealmakers since 2010
  • The leading antibiotics partnering resources

In Global Antibiotics Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Antibiotics Partnering Terms and Agreements 2010 to 2016 provides the reader with the following key benefits:

  • In-depth understanding of antibiotics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of antibiotics agreements with numerous real life case studies
  • Comprehensive access to over 200 antibiotics deals entered into by the world's biopharma companies, together with real world clause examples and contracts where available
  • Full listing of antibiotics deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading antibiotics deals by value since 2010
  • Identify the most active antibiotics dealmakers since 2010
  • Detailed access to actual antibiotics contracts enter into by the leading fifty big pharma and big biotech companies
  • Insight into the terms included in a antibiotics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibiotics dealmaking

  • 2.1. Introduction
  • 2.2. Antibiotics partnering over the years
  • 2.3. Most active antibiotics dealmakers
  • 2.4. Antibiotics partnering by deal type
  • 2.5. Antibiotics partnering by therapy area
  • 2.6. Antibiotics partnering by industry sector
  • 2.7. Deal terms for antibiotics partnering
    • 2.7.1 Antibiotics partnering headline values
    • 2.7.2 Antibiotics deal upfront payments
    • 2.7.3 Antibiotics deal milestone payments
    • 2.7.4 Antibiotics royalty rates
  • 2.8. The anatomy of an antibiotics deal
    • 2.8.a. Case study 1: RRD International & Dipexium Pharmaceuticals -Feb 03 2014
    • 2.8.b. Case study 2: Hospira & Cempra Pharmaceutical- July 01 2013
    • 2.8.c. Case study 3: Astellas & Optimer Pharmaceuticals- Feb 7 2011

Chapter 3 - Leading antibiotics deals

  • 3.1. Introduction
  • 3.2. Top antibiotics deals by value

Chapter 4 - Most active antibiotics dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibiotics dealmakers
  • 4.3. Most active antibiotics partnering company profiles

Chapter 5 - Antibiotics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibiotics contracts dealmaking directory

Chapter 6 - Antibiotics dealmaking by technology type

  • Antibiotics
  • Aminoglycosides
  • Cephalosporin
  • Clindamycin
  • Macrolides
  • Metronidazole
  • Penicillin
  • Quinolones
  • Tetracycline

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Antibiotics deals by company A-Z
  • Appendix 2 - Antibiotics deals by stage of development
  • Appendix 3 - Antibiotics deals by deal type
  • Appendix 4 - Antibiotics deals by therapy area
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Antibiotics partnering since 2010
  • Figure 2: Active antibiotics dealmaking activity- 2010 to 2016
  • Figure 3: Antibiotics partnering by deal type since 2010
  • Figure 4: Antibiotics partnering by disease type since 2010
  • Figure 5: Antibiotics partnering by industry sector since 2010
  • Figure 6: Antibiotics deals with a headline value
  • Figure 7: Antibiotics deals with an upfront value
  • Figure 8: Antibiotics deals with a milestone value
  • Figure 9: Antibiotics deals with a royalty rate value
  • Figure 10: Top antibiotics deals by value since 2010
  • Figure 11: Most active antibiotics dealmakers 2010 to 2016
  • Figure 12: Antibiotics partnering by technology type since 2010
  • Figure 13: Online partnering resources
  • Figure 14: Forthcoming partnering events
Back to Top